GLPwatch
Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus.
World J Diabetes · 2024
Last updated 2026-05-28The first GLP-1 drug for type 2 diabetes, exenatide, was approved in 2005, and since then, several similar drugs have been developed. In 2022, tirzepatide—a dual-action drug targeting both GIP and GLP-1—was approved. These drugs are generally safe and do not cause low blood sugar, making them a common second treatment option after metformin.
AI summary of the abstract below.
| Journal | World J Diabetes, 2024 |
|---|---|
| Citations | 4 |
| Relative citation ratio | 0.94 |
| NIH percentile | 48 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
In 2005, exenatide became the first approved glucagon-like peptide-1 receptor agonist (GLP-1 RA) for type 2 diabetes mellitus (T2DM). Since then, numerous GLP-1 RAs have been approved, including tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA, which was approved in 2022. This class of drugs is considered safe with no hypoglycemia risk, making it a common second-line choice after metformin for treating T2DM. Various considerations can make selecting and switching between different GLP-1 RAs challenging. Our study aims to provide a comprehensive guide for the usage of GLP-1 RAs and dual GIP and GLP-1 RAs for the management of T2DM.
Verbatim abstract via PubMed 38591071 ↗